PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT05064800
- Locations
- 🇺🇸
Research Centers of America ( Hollywood ), Hollywood, Florida, United States
Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative Colitis
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 54
- Registration Number
- NCT05061446
- Locations
- 🇯🇵
NHO Hirosaki General Medical Center, Hirosaki-shi, Aomori-ken, Japan
🇯🇵Our Lady of the Snow St. Mary's Hospital, Kurume, Fukuoka, Japan
🇯🇵Kudo Internist Heart Clinic, Morioka-shi, Iwate-ken, Japan
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
- Conditions
- Renal Cell CancerSquamous Cell CarcinomaSarcomaColorectal CancerBladder CancerHead and Neck CancerMelanomaNon-Small-Cell Lung CancerHepatocellular CancerOvarian Cancer
- Interventions
- Biological: PF-07263689Biological: Sasanlimab
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 13
- Registration Number
- NCT05061537
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
🇺🇸CUMC Research Pharmacy, New York, New York, United States
Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Recifercept in Healthy Chinese Participants
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Pfizer
- Registration Number
- NCT05061277
- Locations
- 🇨🇳
Huashan Hospital Fudan University, Shanghai, Shanghai, China
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
- Conditions
- Advanced MalignanciesNSCLCOvarian CancerUrothelial CancerSolid Tumors
- Interventions
- First Posted Date
- 2021-09-28
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 67
- Registration Number
- NCT05059522
- Locations
- 🇺🇸
Highlands Oncology Group, PA, Springdale, Arkansas, United States
🇷🇺Budgetary Healthcare Institution of Omsk Region "Clinical Oncology Dispensary", Omsk, Omskaya Oblast', Russian Federation
🇺🇸MSK Monmouth, Middletown, New Jersey, United States
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza
- Conditions
- Influenza, Human
- Interventions
- Biological: mIRVBiological: bIRV ABBiological: qIRVBiological: QIVBiological: bIRV AABiological: bIRV BB
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1158
- Registration Number
- NCT05052697
- Locations
- 🇺🇸
NYU Langone Cardiology Associates, Delray Beach, Florida, United States
🇺🇸Robert B. Pritt, DO, Fort Myers, Florida, United States
🇺🇸Orange County Research Center, Tustin, California, United States
Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]-PF-07304814 in Healthy Participants
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2022-05-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 5
- Registration Number
- NCT05050682
- Locations
- 🇺🇸
Labcorp Clinical Research Unit, Madison, Wisconsin, United States
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2954
- Registration Number
- NCT05047601
- Locations
- 🇺🇸
Accellacare, Ames, Iowa, United States
🇨🇴Clinica de la Costa LTDA., Barranquilla, Atlantico, Colombia
🇭🇺Medifarma-98 Kft., Nyiregyhaza, Hungary
Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
- Conditions
- Migraine
- Interventions
- Other: RimegepantOther: Not taking Rimegepant
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 780
- Registration Number
- NCT05046613
- Locations
- 🇺🇸
PPD, Morrisville, North Carolina, United States
European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies
- Conditions
- Metastatic Breast Cancer
- Interventions
- Drug: Aromatase inhibitor
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1939
- Registration Number
- NCT05043506
- Locations
- 🇸🇪
Örebro University Hospital, Örebro, Sweden
🇩🇪Medizinische Studiengesellschaft NORD-WEST GmbH, Westerstede, Germany
🇩🇪Ruppiner Kliniken GmbH, Neuruppin, Ostprignitz-ruppin, Germany